



PRESS RELEASE

Company Contact:

Elizabeth Hutt
Vice President, Sales and Technical Service
650-590-3600
ehutt@nugeninc.com

Media Contact:

Carolyn Hawley
Atkins + Associates for NuGEN Technologies
858-527-3484
chawley@irpr.com

NuGEN Strengthens Intellectual Property Portfolio and Expands Protection for Nucleic Acid Technologies

San Carlos, California, November 9, 2004 - NuGEN Technologies, Inc., a privately held company developing and commercializing the new standard for nucleic acid amplification and labeling, announced today that the United States Patent and Trademark Office issued U.S. Patent No 6,815,164, which is directed towards novel nucleic acid detection methods and probes for the detection of specific nucleic acid sequences. The methods use a multiple probe system for proximity-dependent detection, and generic probe design parameters. These attributes provide simple and widely applicable methods for highly specific detection and quantification of nucleic acid sequences.

"The issuance of this patent further strengthens NuGEN's patent position and our competitive position in the marketplace. The newly issued U.S. patent is adding to our growing patent portfolio, which includes patents related to nucleic acid amplification, labeling, and detection," said Jan D'Alvise, President and CEO of NuGEN.

About NuGEN Technologies Inc.

NuGEN Technologies is focused on the development and commercialization of sensitive, rapid and cost-effective amplification and detection systems for genomic and proteomic research. The company's technologies enable the comprehensive analysis and discovery of biological mechanisms, cellular responses, and disease pathologies. NuGEN's proprietary SPIA(TM) and Ribo-SPIA(TM) amplification and labeling technology for DNA and RNA based applications, form the foundation for a wide range of methods and products used by life scientists. The Ovation(TM) amplification and labeling system, the company's first commercially available product line, has applied these technologies to enhancing the sensitivity, convenience, and accuracy of gene expression analysis. Based in San Carlos, CA, NuGEN has a world-class investor syndicate, several collaborations with leading academic and commercial organizations and a management team with significant experience developing and marketing products for research or clinical diagnostic applications.

NuGEN is a trademark of NuGEN Technologies, Inc.

This press release contains forward-looking statements that are subject to risks and uncertainties, including continued growth in demand by researchers for total RNA analysis, continued use of oligo and cDNA microarrays, acceptance by researchers of the Company's technologies and products, and competition from existing and newly developed products. Accordingly, actual results may differ materially from those anticipated. These forward-looking statements represent the Company's current expectations as of the date of this release. The Company disclaims, however, any intent or obligation to update these forward-looking statements.